Lip, Oral Cavity and Pharynx, Phase II
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Volunteers
Health Professionals
What is the purpose of this trial?
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial withGlaxoSmithKline, LLC
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Andrea Brennan
- Barbara Burtness, MD
- Clarice Grens
- Emily Collier, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jose Morales-Marin
- Karishma Mehra, MBBS
- Kayla Martello
- Laura Sabourin
- Lynsey Teulings
- Madeline Santiago
- Michael Chiorazzi, MD, PhD
- Neal Fischbach, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Renee Moye
- Vidya Kesavan
- Last Updated11/14/2024
- Study HIC#2000036332